{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:54:53Z","timestamp":1792608893746,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Key Basic Research Program of China","award":["2015CB553706"],"award-info":[{"award-number":["2015CB553706"]}]},{"name":"ational Major Scientific and Technological Special Project, China","award":["2013ZX09102040"],"award-info":[{"award-number":["2013ZX09102040"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31270987"],"award-info":[{"award-number":["31270987"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31470896"],"award-info":[{"award-number":["31470896"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Suzhou Science and Technology Project, China","award":["ZXY2012029"],"award-info":[{"award-number":["ZXY2012029"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.canlet.2016.04.036","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T02:39:23Z","timestamp":1461983963000},"page":"164-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects"],"prefix":"10.1016","volume":"377","author":[{"given":"Dong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2016.04.036_bib0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2016.04.036_bib0015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00109-013-0993-5","article-title":"Ocular neovascularization","volume":"91","author":"Campochiaro","year":"2013","journal-title":"J. Mol. Med"},{"key":"10.1016\/j.canlet.2016.04.036_bib0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2007.01.006","article-title":"Vascular endothelial growth factor (VEGF) signaling in tumor progression","volume":"62","author":"Roskoski","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol"},{"key":"10.1016\/j.canlet.2016.04.036_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","article-title":"Vascular endothelial growth factors and angiogenesis in eye disease","volume":"22","author":"Witmer","year":"2003","journal-title":"Prog. Retin. Eye Res"},{"key":"10.1016\/j.canlet.2016.04.036_bib0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cytogfr.2005.01.004","article-title":"Fibroblast growth factor\/fibroblast growth factor receptor system in angiogenesis","volume":"16","author":"Presta","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.canlet.2016.04.036_bib0035","first-page":"7163","article-title":"Fibroblast growth factors are required for efficient tumor angiogenesis","volume":"60","author":"Compagni","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2016.04.036_bib0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.clgc.2012.01.010","article-title":"Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy","volume":"10","author":"Saylor","year":"2012","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.canlet.2016.04.036_bib0045","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3748\/wjg.v10.i17.2524","article-title":"Angiogenic synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in an in vitro quantitative microcarrier-based three-dimensional fibrin angiogenesis system","volume":"10","author":"Sun","year":"2004","journal-title":"World J. Gastroenterol"},{"key":"10.1016\/j.canlet.2016.04.036_bib0050","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/S0002-9440(10)64325-8","article-title":"Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis","volume":"162","author":"Giavazzi","year":"2003","journal-title":"Am. J. Pathol"},{"key":"10.1016\/j.canlet.2016.04.036_bib0055","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bcp.2010.09.023","article-title":"Antiangiogenic agents and targets: a perspective","volume":"81","author":"Teicher","year":"2011","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.canlet.2016.04.036_bib0060","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1634\/theoncologist.12-6-713","article-title":"FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced\/metastatic recurrent nonsquamous non-small cell lung cancer","volume":"12","author":"Cohen","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2016.04.036_bib0065","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme","volume":"14","author":"Cohen","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2016.04.036_bib0070","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2016.04.036_bib0075","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1167\/iovs.10-6798","article-title":"Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog","volume":"52","author":"Lutty","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"10.1016\/j.canlet.2016.04.036_bib0080","first-page":"842","article-title":"FDA approves aflibercept (Zaltrap) for metastatic colorectal cancer","volume":"26","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.canlet.2016.04.036_bib0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1586\/ecp.12.81","article-title":"Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration","volume":"6","author":"Stewart","year":"2013","journal-title":"Expert Rev. Clin. Pharmacol"},{"key":"10.1016\/j.canlet.2016.04.036_bib0090","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1158\/1078-0432.CCR-07-5287","article-title":"Pathways mediating resistance to vascular endothelial growth factor-targeted therapy","volume":"14","author":"Ellis","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2016.04.036_bib0095","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2016.04.036_bib0100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2016.04.036_bib0105","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1541-7786.MCR-13-0358","article-title":"A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma","volume":"11","author":"Gyanchandani","year":"2013","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/j.canlet.2016.04.036_bib0110","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1073\/pnas.0607542104","article-title":"Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis","volume":"104","author":"Dorrell","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2016.04.036_bib0115","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2009.24.8252","article-title":"Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance","volume":"28","author":"Kopetz","year":"2010","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2016.04.036_bib0120","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1158\/1078-0432.CCR-10-2847","article-title":"Brivanib, a dual FGF\/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive\/evasive resistance to VEGF inhibition","volume":"17","author":"Allen","year":"2011","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2016.04.036_bib0125","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.coi.2008.06.012","article-title":"Molecular engineering and design of therapeutic antibodies","volume":"20","author":"Presta","year":"2008","journal-title":"Curr. Opin. Immunol"},{"key":"10.1016\/j.canlet.2016.04.036_bib0130","doi-asserted-by":"crossref","first-page":"178ra139","DOI":"10.1126\/scitranslmed.3005414","article-title":"Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer","volume":"5","author":"Harding","year":"2013","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.canlet.2016.04.036_bib0135","first-page":"101","article-title":"Oxygen-induced retinopathy in the mouse","volume":"35","author":"Smith","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"10.1016\/j.canlet.2016.04.036_bib0140","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/bjc.2014.282","article-title":"A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth","volume":"111","author":"Li","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2016.04.036_bib0145","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nm0398-336","article-title":"Vascular endothelial growth factor is essential for corpus luteum angiogenesis","volume":"4","author":"Ferrara","year":"1998","journal-title":"Nat. Med"},{"key":"10.1016\/j.canlet.2016.04.036_bib0150","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/9467","article-title":"VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation","volume":"5","author":"Gerber","year":"1999","journal-title":"Nat. Med"},{"key":"10.1016\/j.canlet.2016.04.036_bib0155","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1083\/jcb.141.7.1659","article-title":"Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis","volume":"141","author":"Seghezzi","year":"1998","journal-title":"J. Cell Biol"},{"key":"10.1016\/j.canlet.2016.04.036_bib0160","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1439-0531.2004.00517.x","article-title":"Expression pattern of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) system members in bovine corpus luteum endothelial cells during treatment with FGF-2, VEGF or oestradiol","volume":"39","author":"Gabler","year":"2004","journal-title":"Reprod. Domest. Anim"},{"key":"10.1016\/j.canlet.2016.04.036_bib0165","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1158\/1078-0432.CCR-06-1520","article-title":"Vascular endothelial growth factor signaling pathways: therapeutic perspective","volume":"12","author":"Kowanetz","year":"2006","journal-title":"Clin. Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.canlet.2016.04.036_bib0170","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.9-suppl_1-2","article-title":"Vascular endothelial growth factor as a target for anticancer therapy","volume":"9","author":"Ferrara","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2016.04.036_bib0175","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.mce.2011.10.018","article-title":"Adipocyte-secreted factors increase osteoblast proliferation and the OPG\/RANKL ratio to influence osteoclast formation","volume":"349","author":"Kuhn","year":"2012","journal-title":"Mol. Cell. Endocrinol"},{"key":"10.1016\/j.canlet.2016.04.036_bib0180","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/nprot.2009.187","article-title":"Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis","volume":"4","author":"Connor","year":"2009","journal-title":"Nat. Protoc"},{"key":"10.1016\/j.canlet.2016.04.036_bib0185","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00417-009-1058-x","article-title":"Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis","volume":"247","author":"Stahl","year":"2009","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516302725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516302725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T18:24:44Z","timestamp":1536776684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383516302725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0304383516302725"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2016.04.036","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2016.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}